Genscript Biotech Corporation Cash Flow Reinvestment Rate
Genscript Biotech Corporation cash flow reinvestment rate. Genscript Biotech Corporation (G51) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting €0.00 (capex €0.00 ) from operating cash flow of €61.62 Million. Explore debt repayment capacity of Genscript Biotech Corporation to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Genscript Biotech Corporation (2016–2025)
Cash flow reinvestment rate of Genscript Biotech Corporation from 2016 to 2025. Historical reinvestment intensity for Genscript Biotech Corporation across 5 annual periods. Explore G51 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Genscript Biotech Corporation Cash Flow Reinvestment Rate by Year (2016–2025)
Genscript Biotech Corporation cash flow reinvestment rate by year from 2016 to 2025. Year-by-year capital reinvestment analysis for Genscript Biotech Corporation. For the full cash flow conversion analysis, see G51 cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | €147.45 Million | €325.52 Million | €83.84 Million | ▼ -96.4% |
| 2024 | 12.49x | €945.21 Million | €75.65 Million | €147.92 Million | ▲ +2502.3% |
| 2018 | 0.48x | €147.72 Million | €307.66 Million | €70.84 Million | ▼ -69.9% |
| 2017 | 1.60x | €34.09 Million | €21.37 Million | €29.21 Million | ▲ +206.9% |
| 2016 | 0.52x | €17.30 Million | €33.27 Million | €8.98 Million | — |